- Home
- NEGG vs PGEN Comparison
NEGG vs PGEN Comparison
Compare NEGG & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- PGEN
- Stock Information
- Founded
- NEGG 2001
- PGEN 1998
- Country
- NEGG United States
- PGEN United States
- Employees
- NEGG N/A
- PGEN N/A
- Industry
- NEGG Other Specialty Stores
- PGEN Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- PGEN Health Care
- Exchange
- NEGG Nasdaq
- PGEN Nasdaq
- Market Cap
- NEGG 180.8M
- PGEN 292.6M
- IPO Year
- NEGG 2010
- PGEN N/A
- Fundamental
- Price
- NEGG $0.46
- PGEN $0.74
- Analyst Decision
- NEGG
- PGEN Buy
- Analyst Count
- NEGG 0
- PGEN 5
- Target Price
- NEGG N/A
- PGEN $7.00
- AVG Volume (30 Days)
- NEGG 787.1K
- PGEN 1.1M
- Earning Date
- NEGG 01-07-2025
- PGEN 11-14-2024
- Dividend Yield
- NEGG N/A
- PGEN N/A
- EPS Growth
- NEGG N/A
- PGEN N/A
- EPS
- NEGG N/A
- PGEN N/A
- Revenue
- NEGG $1,391,833,000.00
- PGEN $3,963,000.00
- Revenue This Year
- NEGG $6.01
- PGEN N/A
- Revenue Next Year
- NEGG N/A
- PGEN $402.12
- P/E Ratio
- NEGG N/A
- PGEN N/A
- Revenue Growth
- NEGG N/A
- PGEN N/A
- 52 Week Low
- NEGG $0.43
- PGEN $0.65
- 52 Week High
- NEGG $1.45
- PGEN $1.93
- Technical
- Relative Strength Index (RSI)
- NEGG 32.45
- PGEN 43.78
- Support Level
- NEGG $0.43
- PGEN $0.71
- Resistance Level
- NEGG $0.66
- PGEN $0.78
- Average True Range (ATR)
- NEGG 0.05
- PGEN 0.05
- MACD
- NEGG -0.01
- PGEN 0.01
- Stochastic Oscillator
- NEGG 13.43
- PGEN 49.28
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About PGEN Precigen Inc.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.